Zydus Lifesciences Ltd (BOM:532321)
₹ 1050.35 -8.2 (-0.77%) Market Cap: 1.06 Til Enterprise Value: 1.04 Til PE Ratio: 27.99 PB Ratio: 5.42 GF Score: 95/100

Q1 2022 Cadila Healthcare Ltd Earnings Call Transcript

Aug 11, 2021 / 10:30AM GMT
Release Date Price: ₹563.65 (-2.45%)
Ganesh Narayan Nayak
Cadila Healthcare Limited - COO & Executive Director

Good evening, ladies and gentlemen. Welcome to our post results teleconference for the quarter ended June 2021. I do wish that you and your families are keeping safe and well. For today's call, we have with us Dr. Sharvil Patel, Managing Director; Mr. Nitin Parekh, Chief Financial Officer; Mr. Vishal Gor, Senior Vice President, Corporate Finance; and Mr. Alok Gur, Senior Vice President from the Managing Director's office.

This quarter on, we have started the practice of sharing quarterly results, investor presentation, which we have posted on our website and filed with the stock exchange. I'm sure you would have received the same.

Among our 2 key markets, India and the U.S., the contribution from the India geography has increased. This has offset some of the challenges in the U.S. during the quarter, resulting in a healthy double-digit growth in revenues and in EBITDA with an improvement in operating margins. Coming to the quarter, despite the onset of the second wave of COVID-19 in India and the consequent

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot